Table 3.

 Survival and pathological and immunohistochemical parameters in patients with non-small cell lung cancer (univariate analysis)

	Median survival (months)	95% CI	p Value
Tumour stage
I–II	39.83	24.30 to 50.37	0.003
III (A and B)	21.00	19.77 to 30.23
T stage
T1–2	27.00	22.76 to 31.24	0.6480
T3–4	26.00	18.93 to 33.07	0.6480
N stage
N0	26.00	20.40 to 31.60	0.0122
N1–3	32.00	28.86 to 42.44
Grade
G1–2	25.00	16.99 to 33.01	0.8177
G3	27.00	23.09 to 30.91
p53
Negative	34.00	25.00 to 43.00	0.040
Positive	21.00	15.37 to 26.63
p27
Negative	25.00	20.98 to 29.02	0,0279
Positive	40.00	29.14 to 50.86
Cyclin D1
Negative	46.00	39.79 to 52.21	<0.0001
Positive	19.00	16.44 to 21.56
p16
Negative	14.00	10.03 to 17.97	<0.0001
Positive	39.00	30.29 to 47.71
PCNA
Negative	26.00	18.41 to 33.59	0.1164
Positive	30.00	19.99 to 40.01
pRb/p105
Negative	29.00	21.60 to 36.40	0.2318
Positive	25.00	16.35 to 33.65
pRb2/p130
Negative	17.00	12.42 to 21.58	<0.0001
Positive	38.00	28.47 to 47.53

CI, confidence interval; PCNA, proliferating cell nuclear antigen; pRb, retinoblastoma protein.